Name | Nα-(4-Biphenylylsulfonyl)-N-hydroxy-D-phenylalaninamide |
---|---|
Synonyms |
Nα-(4-Biphenylylsulfonyl)-N-hydroxy-D-phenylalaninamide
Benzenepropanamide, α-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-N-hydroxy-, (αR)- Nα-(biphenyl-4-ylsulfonyl)-N-hydroxy-D-phenylalaninamide |
Description | BPHA is a potent and orally active MMP-2, MMP-9 and MMP-14 inhibitor with 50s of 12 nM, 16 nM and 17 nM, respectively. BPHA does not inhibit MMP-1, -3, and -7 (the IC50s are 974, >1000, and 795 nM, respectively). BPHA has antiangiogenic and antitumor effects[1]. |
---|---|
Related Catalog | |
Target |
MMP-2:12 nM (IC50) MMP-9:16 nM (IC50) MMP-14:17 nM (IC50) MMP-1:974 nM (IC50) MMP-3:>1000 nM (IC50) MMP-7:795 nM (IC50) |
In Vitro | BPHA 不抑制典型的丝氨酸蛋白酶(中性粒细胞弹性蛋白酶、纤溶酶、胰蛋白酶和胰凝乳蛋白酶)、半胱氨酸蛋白酶(组织蛋白酶 B 和 L)、天冬氨酸蛋白酶(HIV-1 蛋白酶)或金属蛋白酶(氨肽酶 M)[1]< /sup>。 |
In Vivo | antiangiogenic and antitumor effects, MMP-2, MMP-9, MMP-14, orally active小鼠每日口服 200 mg/kg BPHA 可有效抑制肿瘤诱导的血管生成、原发性肿瘤生长和肝转移。BPHA 在 B16-BL6 黑色素瘤和 F2 血管内皮瘤模型中的生长抑制活性分别为 48% 和 45%[1]。 |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Molecular Formula | C21H20N2O4S |
Molecular Weight | 396.460 |
Exact Mass | 396.114380 |
LogP | 3.23 |
Index of Refraction | 1.630 |